Bibliography
- Burzykowski T, Molenberghs G, Abeck D, High prevalence of foot diseases in Europe: results of the achilles project. Mycoses 2003;46(11-12):496-505
- Ghannoum MA, Hajjeh RA, Scher R, A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000;43(4):641-8
- Gupta AK, Jain HC, Lynde CW, Prevalence and epidemiology of onychomycosis in patients visiting physicians™ offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000;43(2):244-8
- Pierard G. Onychomycosis and other superficial fungal infections of the foot in the elderly: a pan-European survey. Dermatology 2001;202(3):220-4
- Reich A, Szepietowski JC. Health-related quality of life in patients with nail disorders. Am J Clin Dermatol 2011;12(5):313-20
- Baran R. The nail in the elderly. Clin Dermatol 2011;29(1):54-60
- Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 2000;10(5):379-84
- Gupta AK, Gupta MA, Summerbell RC, The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 2000;14(6):466-9
- Gruseck E, Abeck D, Ring J. Relapsing severe trichophyton rubrum infections in an immunocompromised host: evidence of onychomycosis as a source of reinfection based on lectin typing. Mycoses 1993;36(7-8):275-8
- Gupta AK, Taborda P, Taborda V, Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol 2000;39(10):746-53
- Doner N, Yasar S, Ekmekci TR. Evaluation of obesity-associated dermatoses in obese and overweight individuals. Turkderm 2011;45(3):146-51
- Baran R, Gupta AK, Pierard GE. Pharmacotherapy of onychomycosis. Expert Opinion on Pharmacotherapy 2005;6(4):609-24
- Murdan S. 1st meeting on topical drug delivery to the nail. Expert Opin Drug Deliv 2007;4(4):453-5
- Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 2010;62(3):411-14
- Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003;149(Suppl 65):5-9
- Shear N, Drake L, Gupta AK, The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. Dermatology 2000;201(3):196-203
- Krishnan-Natesan S. Terbinafine: a pharmacological and clinical review. Expert Opinion on Pharmacotherapy 2009;10(16):2723-33
- Novartis. Lamisil Product Label. 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020539s018lbl.pdf
- Ghannoum MA, Long L, Pfister WR. Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 2009;52(1):35-43
- Elewski BE, Ghannoum MA, Mayser P, Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol 2011. [Epub ahead of print]
- Ghannoum M, Isham N, Herbert J, Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations. J Clin Microbiol 2011;49(5):1716-20
- Dominicus R, Weidner C, Tate H, Open-label study of the efficacy and safety of topical treatment with TDT 067 (terbinafine in Transfersome(R)) in patients with onychomycosis. Br J Dermatol 2011. [Epub ahead of print]
- Pannu J, McCarthy A, Martin A, NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans. Antimicrob Agents Chemother 2009;53(8):3273-9
- ClinicalTrials.gov. Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail. Available from: http://clinicaltrials.gov/ct2/show/NCT00453271 [Cited 21 December 2011]
- Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009;18(9):1279-95
- Schering. Noxafil Product Label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022003s008,022027s001lbl.pdf [Cited 12 December 2011]
- Elewski B, Pollak R, Ashton S, A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol 2011; [Epub ahead of print]
- Gupta AK, Leonardi C, Stoltz RR, A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2005;19(4):437-43
- Pfizer. VFEND Product Label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021266s035,021267s040,021630s026lbl.pdf [Cited 12 December 2011]
- Carrillo-Munoz AJ, Giusiano G, Guarro J, In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. Int J Antimicrob Agents 2007;30(2):157-61
- ClinicalTrials.gov. A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule. 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01039883 [Cited 12 December 2011]
- ClinicalTrials.gov. Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis. Available from: http://clinicaltrials.gov/ct2/show/NCT00730405 [Cited 12 December 2011]
- Bartroli J, Turmo E, Alguero M, New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. J Med Chem 1998;41(11):1869-82
- Ramos G, Cuenca-Estrella M, Monzon A, In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J Antimicrob Chemother 1999;44(2):283-6
- Schaller M, Borelli C, Berger U, Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. Med Mycol 2009;47(7):753-8
- ClinicalTrials.gov. Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste. Available from: http://clinicaltrials.gov/ct2/show/NCT00781820 [Cited 13 December 2011]
- ClinicalTrials.gov. The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis. Available from: http://clinicaltrials.gov/ct2/show/NCT01007708 [Cited 13 December 2011]
- Fernandez-Torres B, Inza I, Guarro J. Evaluation of disk diffusion method for determining eberconazole susceptibility of dermatophytes and influence of culture medium. Antimicrob Agents Chemother 2005;49(5):2116-18
- Fernandez-Torres B, Inza I, Guarro J. In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes. J Clin Microbiol 2003;41(11):5209-11
- ClinicalTrials.gov. Open-Label Pharmacokinetics (PK)/Safety Study of Luliconazole Solution, 10% in Distal Subungual Onychomycosis. Available from: http://clinicaltrials.gov/ct2/show/NCT01044381 [Cited 12 December 2011]
- ClinicalTrials.gov. Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis (SOLUTION). Available from: http://clinicaltrials.gov/ct2/show/NCT01431820 [Cited 12 December 2011]
- Ghannoum MA, Long L, Kim HG, Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model. Med Mycol 48(3):491-7
- Koga H, Nanjoh Y, Makimura K, In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol 2009;47(6):640-7
- Koga H, Tsuji Y, Inoue K, In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother 2006;12(3):163-5
- Topica Pharmaceuticals. Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis (SOLUTION). 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT01431820
- Uchida K, Nishiyama Y, Yamaguchi H. In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother 2004;10(4):216-19
- Vanden Bossche H, Ausma J, Bohets H, The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp, and Microsporum canis. Antimicrob Agents Chemother 2004;48(9):3272-8
- Odds F, Ausma J, Van Gerven F, In vitro and in vivo activities of the novel azole antifungal agent r126638. Antimicrob Agents Chemother 2004;48(2):388-91
- Baker SJ, Zhang YK, Akama T, Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 2006;49(15):4447-50
- Rock FL, Mao W, Yaremchuk A, An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007;316(5832):1759-61
- Hui X, Baker SJ, Wester RC, In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci 2007;96(10):2622-31
- Benter K, Toledo-Bahena M, Barbosa-Alanis H, Interim Results of a Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solutions for the Treatment of Onychomycosis of the Great Toenail. J Am Acad Dermatol 2009;60(3 Suppl):AB116
- ClinicalTrials.gov. Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail. Available from: http://clinicaltrials.gov/ct2/show/NCT01270971 [Cited 14 December 2011]
- ClinicalTrials.gov. Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail. Available from: http://clinicaltrials.gov/ct2/show/NCT01302119 [Cited 14 December 2011]
- Mao W, Seiradake E, Crepin T, AN2718 has Broad Spectrum Antifungal Activity Necessary for the Topical Treatment of Skin and Nail Fungal Infections. J Am Acad Dermatol 2007:56(2 Suppl):AB124
- ClinicalTrials.gov. Cumulative Irritation Test. Available from: http://clinicaltrials.gov/ct2/show/NCT00781664 [Cited 11 December 2011]
- Pound MW, Townsend ML, Dimondi V, Overview of treatment options for invasive fungal infections. Med Mycol 2011;49(6):561-80
- Astellas. Mycamine Product label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021506s011s012lbl.pdf [Cited 16 December 2011]
- Merck & Co, Inc. Candicas Product Label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021227s028lbl.pdf [Cited 16 December 2011]
- Pfizer. Eraxis Product Label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021632s000,021948s000lbl.pdf [Cited 16 December 2011]
- Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009;43(10):1647-57
- Nasir A, Goldstein B, van Cleeff M, Clinical evaluation of safety and efficacy of a new topical treatment for onychomycosis. J Drugs Dermatol 2011;10(10):1186-91
- Gilaberte Y, Aspiroz C, Martes MP, Treatment of refractory fingernail onychomycosis caused by nondermatophyte molds with methylaminolevulinate photodynamic therapy. J Am Acad Dermatol 2010;65(3):669-71
- Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by trichophyton rubrum. J Am Acad Dermatol 2008;59(5 Suppl):S75-6
- Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by trichophyton rubrum: preliminary results of a single-centre open trial. Acta Derm Venereol 2010;90(2):216-17
- Watanabe D, Kawamura C, Masuda Y, Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol 2008;144(1):19-21
- Harris F, Pierpoint L. Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev 2011. [Epub ahead of print]
- Smijs TG, Schuitmaker HJ. Photodynamic inactivation of the dermatophyte Trichophyton rubrum. Photochem Photobiol 2003;77(5):556-60
- Smijs TG, van der Haas RN, Lugtenburg J, Photodynamic treatment of the dermatophyte Trichophyton rubrum and its microconidia with porphyrin photosensitizers. Photochem Photobiol 2004;80(2):197-202
- Smijs TG, Bouwstra JA, Talebi M, Investigation of conditions involved in the susceptibility of the dermatophyte Trichophyton rubrum to photodynamic treatment. J Antimicrob Chemother 2007;60(4):750-9
- Smijs TG, Bouwstra JA, Schuitmaker HJ, A novel ex vivo skin model to study the susceptibility of the dermatophyte Trichophyton rubrum to photodynamic treatment in different growth phases. J Antimicrob Chemother 2007;59(3):433-40
- Smijs TG, Mulder AA, Pavel S, Morphological changes of the dermatophyte Trichophyton rubrum after photodynamic treatment: a scanning electron microscopy study. Med Mycol 2008;46(4):315-25
- Smijs TG, Pavel S, Talebi M, Preclinical studies with 5,10,15-Tris(4-methylpyridinium)-20-phenyl-[21H,23H]-porphine trichloride for the photodynamic treatment of superficial mycoses caused by Trichophyton rubrum. Photochem Photobiol 2009;85(3):733-9
- Smijs TG, Pavel S. The susceptibility of dermatophytes to photodynamic treatment with special focus on trichophyton rubrum. Photochem Photobiol 2011;87(1):2-13
- ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/results?term=onychomycosis+photodynamic+therapy [Cited 19 December 2011]
- Amichai B, Nitzan B, Mosckovitz R, Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol 2009;162(1):46-50
- Transport Pharmaceuticals. Iontophoretic Application of Terbinafine Gel to the Large Toe Nail. 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00768768 [Cited 9 November 2011]
- Nitric BioTherapeutics, Inc. Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail. Available from: http://clinicaltrials.gov/ct2/show/NCT01484145 [Cited 5 January 2012]
- Kozarev J. Summary: clearsteps – laser onychomycosis treatment: assessment of efficacy 12 months after treatment and beyond. J Laser Health Acad 2011;2011(1):S07
- Kozarev J, Vizintin Z. Novel laser therapy in treatment of onychomycosis. J Laser Health Acad 2010;1:1-8
- FDA 510(k) Summary K111483. Joule ClearSense, Sciton, Inc. 2011. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K111483.pdf
- FDA 510(k) Summary K093547. PinPointe FootLaser, PinPointe USA, Inc. 2010. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf9/K093547.pdf
- Harris DM, McDowell BA, Stristower J. Laser treatment for toenail fungus. Proc SPIE 2009;71610(M):1-7
- FDA 510(k) Summary K103626. Cutera GenesisPlus Laser System, Cutera, Inc. 2010. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf10/K103626.pdf
- Weiss D. 3 Month Clinical Results using Sub-Millisecond 1064 nm Nd:YAG Laser for the Treatment of Onychomycosis. 2011. Available from: http://www.weissfootandankle.com/resources/White%20Paper_Dr%z20Weiss.pdf [Cited 21 December 2011]
- CoolTouch, Inc. CoolBreeze Features. 2011. Available from: http://www.cooltouch.com/CoolBreeze_laser_features.aspx [Cited 23 December 2011]
- CoolTouch, Inc. CoolTouch CT3Plus Laser Specifications. 2011. Available from: http://www.cooltouch.com/CT3Plus_specifications.aspx [Cited 23 December 2011]
- FDA 510(k) Summary K110370. Q-Clear, Light Age, Inc. 2011. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K110370.pdf [Cited 24 October 2011]
- Bornstein E. A review of current research in light-based technologies for treatment of podiatric infectious disease states. J Am Podiatr Med Assoc 2009.99(4):348-52
- Bornstein E, Hermans W, Gridley S, Near-infrared photoinactivation of bacteria and fungi at physiologic temperatures. Photochem Photobiol 2009;85(6):1364-74
- Landsman AS, Robbins AH, Angelini PF, Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc 2010;100(3):166-77
- ClinicalTrials.gov. Diode Laser Treatment of Onychomycosis. 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT01452490 [Cited 9 November 2011]
- Vural E, Winfield HL, Shingleton AW, The effects of laser irradiation on trichophyton rubrum growth. Lasers Med Sci 2008;23(4):349-53
- Hochman LG. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. J Cosmet Laser Ther 2011;13(1):2-5
- Waibel J. Introducing the Sciton ClearSense Accessory featuring the ClearToe treatment for Onychomycosis (For Non-U.S. Customers). 2011. Available from: http://www.sciton.com/node/2388 [Cited 12 January 2012]
- University of California, Irvine. 1320 nm Nd:YAG Laser for Improving the Appearance of Onychomycosis. 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT01498393 [Cited 23 December 2011]
- Manevitch Z, Lev D, Hochberg M, Direct antifungal effect of femtosecond laser on trichophyton rubrum onychomycosis. Photochem Photobiol 2010.86(2):476-9
- Nomir Medical Technologies. Using Light Therapy to Treat Toe Nail Fungus. 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00771732 [Cited 9 November 2011]
- Nomir Medical Technologies. Treating Onychomychosis. 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00776464 [Cited 9 November 2011]